ATAxel Thors

Axel Thors

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Axel Thors has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Trends and Outcomes of Carotid Revascularization for Asymptomatic Carotid Stenosis Among End-Stage-Kidney-Disease Patients on Dialysis from 2010 to 2019

    by Gokul Ramani, Wan-Chi Chan, Zafar Ali, Kunal Patel, Monil Majmundar, Rhythm Vasudeva, Akshaya Gadre, Cyrus Mugunti, Kartik Munshi, Axel Thors, et al.

    INTRODUCTION The role of carotid revascularization for asymptomatic carotid artery stenosis (ACAS) in dialysis-dependent end-stage kidney disease (ESKD) patients remains poorly defined, as these patients have high periprocedural risks and limited long-term survival. This study evaluated the trends in carotid revascularization in this group and studied associated short- and long-term outcomes. METHODS We analyzed the United States Renal Data System (USRDS) to study dialysis-dependent ESKD patients with ACAS who underwent carotid endarterectomy (CEA) or carotid artery stenosis (CAS) between 2010 and 2019. Primary outcomes included trends in CEA and CAS utilization, 30-day stroke or death rates. Secondary outcomes were in-hospital and one-year stroke or death rates. RESULTS Among 11,405 ESKD patients on dialysis with ACAS, 4954 underwent carotid revascularization (4098 CEA; 856 CAS). CEA rates reduced by 55% and CAS by 50% between 2010 and 2019. CAS was associated with a higher 30-day composite stroke or death rate (7.13% vs 4.5%; P=0.0014), in-hospital stroke or death rate (3.39% vs 2.22%, P=0.0433), and 1-year stroke or death rate (33.1% vs 25.4%, PCONCLUSION Carotid revascularization rates for ACAS have declined among dialysis-dependent ESKD patients, yet both CEA and CAS are associated with significant procedure-related stroke and death risk. These support a cautious approach and underscore the need for a more selective and individualized shared decision-making approach in this high-risk population.

  • Prognostic value of the Hospital Frailty Risk Score (HFRS) and outcomes in peripheral artery disease and end-stage kidney disease

    by Monil Majmundar, Chan Wan-Chi, Kunal N Patel, Vidit Majmundar, Rhythm Vasudeva, Kirk A Hance, Adam Ali, George Hajj, Axel Thors, Jinxiang Hu, et al.

    Background: Peripheral artery disease (PAD) and end-stage kidney disease (ESKD) are independent risk factors affecting outcomes like in-hospital mortality. The role of a frailty index in prognosticating outcomes in patients with ESKD and PAD is unknown. We aim to assess the prognostic value of the Hospital Frailty Risk Score (HFRS) and its association with outcomes in these patients. Methods: We identified patients with PAD using data from the United States Renal Data System (USRDS) for the years 2015–2018. These patients were stratified into three categories of frailty risk based on their HFRS, a validated frailty assessment tool using ICD-10 codes: low (< 5), intermediate (5–10), and high risk (> 10) and based on revascularization or not. Primary outcomes included in-hospital mortality and composite of mortality or major amputation. Secondary outcomes encompassed postdischarge mortality and composite of mortality or major amputation at 1 year. Results: Out of 122,649 patients with PAD and ESKD, 4118 underwent revascularization and 118,531 did not. In-hospital outcomes demonstrated a nonlinear relationship and postdischarge outcomes displayed a nearly linear relationship with HFRS, regardless of revascularization status. In both cohorts, the high-risk group was associated with a significantly higher risk of in-hospital mortality/amputation (revascularization: odds ratio [OR] 4.6, 95% CI 3.3–6.2, p < 0.001; no revascularization: OR 3.1, 95% CI 2.8–3.3, p < 0.001) and mortality (revascularization: OR 5.5, 95% CI 3.4–8.7, p < 0.001; no revascularization: OR 5.1, 95% CI 4.6–5.6, p < 0.001) compared with the low-risk group. Conclusion: In patients with ESKD and PAD, the HFRS serves as a valuable predictor of mortality and amputation irrespective of revascularization. This information can support informed decision-making.


  • Open Access

    Prognostic Value of Hospital Frailty Risk Score and Clinical Outcomes in Critical Limb‐Threatening Ischemia and End‐Stage Kidney Disease

    by Monil Majmundar, Wan‐Chi Chan, Vivek Bhat, Kunal N. Patel, Kirk A. Hance, Georges Hajj, Axel Thors, Kamal Gupta

    Background: End‐stage kidney disease (ESKD) is commonly associated with critical limb‐threatening ischemia (CLTI) and frailty. Yet there are no specific tools to predict outcomes of CLTI in ESKD, particularly those that incorporate frailty. We aimed to assess the utility of the medical record–based Hospital Frailty Risk (HFR) score in predicting outcomes of CLTI in ESKD. Methods and Results: We identified patients with ESKD diagnosed with CLTI from the US Renal Data System from 2015 to 2018. These patients were categorized into 3 frailty risk groups on the basis of their HFR scores: low (10), and on the basis of whether they underwent revascularization (endovascular revascularization [ER]/surgical revascularization [SR]) or not (no revascularization). Primary outcomes of interest included in‐hospital composite of death or major amputation and in‐hospital death. We included 49 454 eligible patients, with ER/SR cohort including 19.8% (n=9777). A total of 88.4% (ER/SR) and 90.0% (no revascularization) were frail on the HFR scale. We found a nonlinear association between HFR score and in‐hospital adverse outcomes. In both cohorts, intermediate and high‐risk HFR scores were associated with greater risk of in‐hospital death (high‐risk, ER/SR: odds ratio, 2.7 [95% CI, 1.6–4.8]; P P P P <0.0001). Conclusions: The HFR score can predict risk of in‐hospital death and composite of death or major amputation in patients with ESKD and CLTI. Further data are needed to determine the utility of the HFR score in this population.